Kevin T. Conroy Sells 137,805 Shares of Exact Sciences Corporation (EXAS) Stock

Exact Sciences Corporation (NASDAQ:EXAS) CEO Kevin T. Conroy sold 137,805 shares of the business’s stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $59.14, for a total transaction of $8,149,787.70. Following the completion of the transaction, the chief executive officer now owns 967,867 shares of the company’s stock, valued at $57,239,654.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Exact Sciences Corporation (EXAS) opened at $58.33 on Wednesday. Exact Sciences Corporation has a 52-week low of $13.05 and a 52-week high of $63.60. The company has a quick ratio of 9.98, a current ratio of 10.34 and a debt-to-equity ratio of 0.01.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its earnings results on Monday, October 30th. The medical research company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.07. The firm had revenue of $72.60 million for the quarter, compared to analyst estimates of $65.03 million. Exact Sciences Corporation had a negative return on equity of 30.32% and a negative net margin of 60.71%. Exact Sciences Corporation’s revenue for the quarter was up 158.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.36) earnings per share. equities analysts anticipate that Exact Sciences Corporation will post -1.14 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Stock Observer and is the property of of Stock Observer. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.thestockobserver.com/2017/11/15/kevin-t-conroy-sells-137805-shares-of-exact-sciences-corporation-exas-stock.html.

A number of brokerages have commented on EXAS. Vetr upgraded shares of Exact Sciences Corporation from a “sell” rating to a “hold” rating and set a $36.55 target price for the company in a report on Tuesday, July 25th. Lake Street Capital boosted their target price on shares of Exact Sciences Corporation from $30.00 to $41.00 and gave the stock a “hold” rating in a report on Wednesday, July 26th. Roth Capital boosted their target price on shares of Exact Sciences Corporation from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Wednesday, July 26th. Jefferies Group LLC boosted their target price on shares of Exact Sciences Corporation to $60.00 and gave the stock a “buy” rating in a report on Tuesday, October 31st. Finally, Robert W. Baird boosted their target price on shares of Exact Sciences Corporation from $49.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 31st. Eight equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $49.98.

Hedge funds and other institutional investors have recently modified their holdings of the stock. State of Wisconsin Investment Board purchased a new stake in Exact Sciences Corporation in the second quarter valued at approximately $3,006,000. Victory Capital Management Inc. purchased a new stake in Exact Sciences Corporation in the second quarter valued at approximately $29,450,000. Eagle Asset Management Inc. boosted its position in Exact Sciences Corporation by 19.6% in the second quarter. Eagle Asset Management Inc. now owns 1,857,185 shares of the medical research company’s stock valued at $65,688,000 after buying an additional 304,598 shares during the last quarter. Federated Investors Inc. PA boosted its position in Exact Sciences Corporation by 53.3% in the second quarter. Federated Investors Inc. PA now owns 34,553 shares of the medical research company’s stock valued at $1,222,000 after buying an additional 12,018 shares during the last quarter. Finally, Bank of Nova Scotia purchased a new stake in Exact Sciences Corporation in the second quarter valued at approximately $1,482,000. Hedge funds and other institutional investors own 85.65% of the company’s stock.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply